Drugs / CT-0508
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04660929 | Feb 2021 → Dec 2024 | HER2 positive breast carcinoma, bile duct cancer, breast ductal adenocarcinoma, colorectal cancer +13 | Carisma Therapeutics Inc | Unknown | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-09-01 | Carisma Therapeutics Inc | Results Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit carismatx.com ↗
Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-09-01 | Carisma Therapeutics Inc | Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit carismatx.com ↗ |
| 2023-06-28 | Carisma Therapeutics Inc | Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors carismatx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-0508 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04660929 ↗ |
| Route | Intravenous | “IV administrations” NCT04660929 ↗ |